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Abstract: Cellular cholesterol metabolism, lipid raft formation, and lipoprotein interactions contribute
to the regulation of immune-mediated inflammation and response to pathogens. Lipid pathways
have been implicated in the pathogenesis of bacterial and viral infections, whereas altered lipid
metabolism may contribute to immune dysfunction in autoimmune diseases, such as systemic lupus
erythematosus, multiple sclerosis, and rheumatoid arthritis. Interestingly, dietary cholesterol may
exert protective or detrimental effects on risk, progression, and treatment of different infectious
and autoimmune diseases, although current findings suggest that these effects are variable across
populations and different diseases. Research evaluating the effects of dietary cholesterol, often
provided by eggs or as a component of Western-style diets, demonstrates that cholesterol-rich
dietary patterns affect markers of immune inflammation and cellular cholesterol metabolism,
while additionally modulating lipoprotein profiles and functional properties of HDL. Further,
cholesterol-rich diets appear to differentially impact immunomodulatory lipid pathways across
human populations of variable metabolic status, suggesting that these complex mechanisms may
underlie the relationship between dietary cholesterol and immunity. Given the Dietary Guidelines
for Americans 2015–2020 revision to no longer include limitations on dietary cholesterol, evaluation
of dietary cholesterol recommendations beyond the context of cardiovascular disease risk is
particularly timely. This review provides a comprehensive and comparative analysis of significant and
controversial studies on the role of dietary cholesterol and lipid metabolism in the pathophysiology
of infectious disease and autoimmune disorders, highlighting the need for further investigation in
this developing area of research.
Keywords: dietary cholesterol; immunity; infectious disease; autoimmune disease; inflammation;
lipoprotein metabolism; eggs
1. Introduction
Regulation of the immune system is essential to the maintenance of health and protection
from acute and chronic diseases [1–3]. The initial response to pathogens or tissue injury involves
activation of innate immune system cells, including antigen-presenting macrophages and dendritic
cells, monocytes, granulocytes (neutrophils, basophils, eosinophils), and natural killer cells [4].
Exogenous microbes and endogenous stimuli released from injured host cells serve as pathogen-
(PAMPs) or damage-associated molecular patterns (DAMPs), respectively, which directly bind and
stimulate cognate pattern-recognition receptors, initiating cascades of pro-inflammatory signaling and
immune cell activation [5,6]. Coordinated efforts of antigen-presenting cells lead to selective activation
of adaptive immune cells, including B and T lymphocytes, conferring cell- and antibody-mediated
immunity [7]. Immune responses lead to extensive proliferation of leukocytes and the generation
of cytotoxic and pro-inflammatory mediators that allow for destruction and clearance of the initial
pathogenic stimuli [4]. Resolution of the immune response involves suppression of pro-inflammatory
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cytokines and interleukins, and concomitant increases in anti-inflammatory compounds that promote
tissue healing and return to homeostasis [8].
Disordered immune responses often stem from (1) a failure of immune cells to appropriately
recognize and respond to pathogenic factors; (2) inappropriate recognition and response to self-tissue
(i.e., in the case of autoimmunity); and (3) failure of pro-inflammatory immune responses to adequately
resolve, leading to prolonged, chronic inflammation [8–10]. Dysregulation of the immune system has
been implicated in a broad range of acute and chronic conditions, ranging from increased susceptibility
to infection, autoimmunity, and chronic inflammatory diseases, such as asthma, osteoarthritis,
cardiovascular disease, non-alcoholic fatty liver disease, and cancer [11–17]. Thus, identifying strategies
and interventions aimed at optimizing appropriate immune responses and leukocyte activity may
minimize the risk of acute and chronic diseases.
Research has demonstrated that various dietary patterns and bioactives have the capacity to
modulate innate and adaptive immune responses, as well as immune-mediated inflammation [18–23].
While most extensively evaluated within the context of cardiovascular disease, dietary cholesterol may
serve as an important regulator of immune cell activity and inflammation, with implications for risk
and treatment of infectious disease and chronic autoimmune disorders [24–28]. Understanding the
relationship between dietary cholesterol and immunity is particularly timely, given the removal of
cholesterol intake limitations in the most recent Dietary Guidelines for Americans 2015–2020, as well
as the American Heart Association/American College of Cardiology 2013 lifestyle recommendations
aimed at reducing cardiovascular disease risk [29,30]. This review discusses the role of cholesterol and
lipid metabolism in regulating leukocyte activity, highlighting research that elucidates the impact of
dietary cholesterol on immune function beyond cardiovascular disease.
2. Role of Cholesterol in Immunity
Cellular and systemic cholesterol metabolism play a significant role in the regulation of immune
cell activity [25]. The majority of cellular cholesterol is located within the plasma membrane,
particularly within cholesterol- and sphingomyelin-rich lipid raft regions [31]. Lipid rafts provide
essential structure and scaffolding to allow for recruitment and signaling of immune receptors [23,32].
Cellular cholesterol depletion has been shown to disrupt raft stability and formation, as well as
suppress toll-like receptor 4 (TLR4)- and T cell receptor (TCR)-mediated immune activation and
pro-inflammatory signaling, whereas these processes are enhanced by cholesterol loading [33–37].
Lipid raft content and inflammatory activation of leukocytes may be further modulated through
interactions with lipoproteins, which mediate cholesterol loading and efflux, serve as carriers of
immunomodulating proteins, and directly interact with, and sequester, pathogenic stimuli [25].
Markers of cellular cholesterol metabolism and lipoprotein function have been found to be altered
in models of infectious and chronic diseases, whereas lipid-lowering therapies have been shown to
exhibit variable potential in the treatment of immune disorders [38]. The following sections highlight
the role of lipid rafts and lipoprotein interactions in immunity.
2.1. Role of Cholesterol in the Pathophysiology of Infectious Disease
2.1.1. Role of Lipid Rafts and Lipoprotein Interactions in Bacterial Pathogenesis
In addition to regulating cellular signaling and inflammatory potential, lipid rafts serve as a
point of pathogen association and colonization [39]. Membrane cholesterol within lipid rafts has
been implicated in the pathology of infection by numerous bacterial strains, including Camylobacter
jejuni and Aggregatibacter actinomycetemcomitan, which cause enterocolitis and periodontal disease,
respectively [40–42]. Cholesterol is thought to mediate host cell infection by these Gram-negative
bacterial strains through recognition and binding of the virulence factor cytolethal distending toxin
(CDT), and mediating subsequent translocation of active toxin subunits [40,41]. Helicobacter pylori
infection, which is associated with gastric inflammation, ulcers, and cancer, is additionally mediated
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by interactions between membrane cholesterol and the virulence protein cytotoxin-associated gene
A (CagA), whereas cellular cholesterol depletion by methyl-β-cyclodextrin (MβCD) or lovastatin
was shown to reduce CagA translocation and pro-inflammatory interleukin 8 (IL-8) secretion in
human gastric adenocarcinoma AGS cells [43,44]. Cellular cholesterol content of host cells has also
been implicated in infection by multiple Chlamydia species associated with urogenital tract infections
and respiratory pneumonia (C. trachomatis and C. pneumonia)[45,46], tick-borne pathogens Anaplasma
phagocytophilium and Ehrlichia chaffeensis [47], as MβCD-mediated depletion of membrane cholesterol
impairs various stages of bacterial infection.
Lipoproteins and their associated transporters additionally impact immune function and
disease pathogenesis. Deletion of macrophage-specific ATP-binding cassette transporter A 1
(ABCA1), which effluxes cholesterol and phospholipids to apolipoprotein A 1 (apoA1) to form
HDL, is associated with increased lipid raft formation and hyper-responsiveness to TLR2, TLR4,
TLR7, and TLR9 ligands [48]. Myeloid cell-specific deletion of ABCA1 has additionally been shown
to promote enhanced inflammatory immune responses and clearance of Listeria monocytogenes in
mice [34], whereas upregulation of HDL pathways may improve response to bacterial pathogens
in other models. In addition to mediating cholesterol efflux, HDL and other lipoproteins can
bind and neutralize Gram-negative bacteria-derived lipopolysaccharide (LPS) and Gram-positive
bacteria-derived lipoteichoic acid (LTA), thereby suppressing inflammatory immune responses
and promoting pathogen clearance [49–51]. Accordingly, higher levels of serum HDL-cholesterol,
reconstituted HDL infusion, and apoA1 overexpression have been shown to improve clinical outcomes
of sepsis [52–55].
It is also important to note that bacterial infections disrupt cellular and systemic lipid metabolism.
C. pneumonia infection has been shown to increase LDL uptake, suppress expression of ABCA1 and
ABCG1, and reduce cholesterol efflux to apoA1, leading to greater cholesterol loading of host cells that
promotes bacterial propagation [56,57]. Plasma cholesterol levels—particularly HDL-cholesterol—are
rapidly reduced in severe sepsis, and HDL particle composition is altered to contain greater levels of
pro-inflammatory serum amyloid A (SAA), and reduced apoA1, apoM and sphingosine-1-phosphate
(S1P), thus impairing the cholesterol efflux and anti-inflammatory properties of HDL [38,58–60].
2.1.2. Role of Lipid Rafts and Lipoprotein Interactions in Viral Infection
In addition to bacterial pathogenesis, membrane cholesterol within lipid rafts plays an important
role in viral infection. Danthi and Chow [61] demonstrated that MβCD-mediated membrane
cholesterol depletion inhibited uptake of poliovirus, whereas repletion of cellular cholesterol partially
restored viral uptake levels. Influenza viruses that encode hemagglutinin and neuraminidase have
similarly been shown to associate with lipid rafts [62], whereas statin treatment has been shown to
have both beneficial and neutral effects on reducing influenza-related morbidity and mortality [63–65].
Interestingly, statin usage reduces influenza vaccine efficacy against influenza A (H3N2), but not
the pandemic influenza A (H1N1) or influenza B viral strains [66]. These findings suggest that
anti-inflammatory properties of statins may lead to suppressive immune responses that impact
strain-specific viral immunity [67,68].
Similar to mechanisms of bacterial pathogenesis, HDL and its associated efflux transporters have
been implicated in human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection [69,70].
HIV infection has been shown to suppress ABCA1-mediated efflux via the viral accessory protein
Nef, promoting viral replication [69,71]. Accordingly, upregulation of ABCA1 by liver X receptor
(LXR) activation and all-trans retinoic acid reduces T lymphocyte cholesterol content and inhibits
HIV replication [72,73]. Conversely, HDL-mediated pathways may promote HCV infection [38].
HCV can be carried and sequestered by HDL and other lipoproteins, protecting the virus from
neutralizing antibodies [70]. Cellular uptake of HCV is thought to be mediated by a variety of
receptors—including the LDL-receptor and scavenger receptor class B type I (SR-BI), the latter of
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which facilitates bidirectional cholesterol exchange with HDL [74–76]. Thus, HDL may play opposing
roles in the inhibition or promotion of different viral infections.
Interestingly, in a recent study assessing 106,553 individuals from the Copenhagen General
Population and Copenhagen City Heart studies, both low (<31 mg/dL) and very high (>100 mg/dL)
HDL-cholesterol levels were shown to be associated with an increased risk of infectious disease [77].
Low HDL-cholesterol appeared to have a greater impact on infectious disease risk, with a 75% increased
risk of disease, vs. a 43% increased risk in individuals with very high HDL-cholesterol [77]. In line
with the findings outlined above, it is plausible that elevated HDL may promote infection by certain
pathogens, or that elevated HDL-cholesterol levels may be indicative of impaired HDL clearance via
reverse cholesterol transport or greater levels of dysfunctional HDL [38,70,78,79].
2.2. Role of Cholesterol in the Pathophysiology of Autoimmune Disease
In addition to infectious disease pathways, cholesterol metabolism appears to play an important
role in autoimmune disease. In patients with systemic lupus erythematous (SLE), T lymphocytes
exhibit greater degrees of lipid raft formation and altered raft composition, leading to increased
TCR-mediated signaling and inflammation [80,81]. Statins have been shown to mitigate inflammatory
dysfunction in animal and ex vivo cell models of lupus [82,83], but have not been found to improve
SLE Disease Activity Index (SLEDAI) scores—a measure of clinical disease status [84]. Activated T cell
populations have additionally been observed in synovial joint fluid from rheumatoid arthritis (RA)
patients, whereas conflicting studies have found that statin treatment may decrease or increase risk for
developing RA [85–88].
In contrast to hyperlipidemic trends in certain autoimmune conditions, metabolomic analysis has
shown that cholesterol levels in bronchoalveolar lavage fluid are reduced in ovalalbumin-sensitized
BALB/c mouse models of asthma, whereas cholesterol content is normalized by dexamethasone
treatment [89]. Pulmonary cholesterol levels were negatively correlated with numbers of macrophages,
eosinophils, neutrophils, and lymphocytes, in contrast to research on other disorders suggesting that
cholesterol loading promotes leukocytosis of pro-inflammatory cell types [36,89]. Fessler et al. [90]
additionally found that serum total cholesterol and non-HDL-cholesterol levels were lower in asthma
patients in the 2005–2006 National Health and Examination Survey dataset. Peng and Huang [91]
found age-specific associations in a recent meta-analysis, in that HDL-cholesterol levels were reduced
in children in asthma, whereas LDL-cholesterol levels were elevated in asthmatic adults. From these
findings, it is unclear whether altered cholesterol levels are a result of asthma, or whether lipoprotein
metabolism contributes to disease progression.
Similar to observations in infectious disease, altered lipoprotein patterns and dysfunctional
HDL have been identified in patients with SLE, RA, asthma, and psoriasis [91–94]. In addition to
dysregulated lipid metabolism perpetuating the progression of immune disorders, affected patients
often have an increased risk of cardiovascular disease [95,96]. Thus, therapies that target pathways of
immune inflammation and lipid metabolism likely serve to reduce complications associated with both
the primary disorder and related comorbidities.
2.3. Summary: Role of Cholesterol in Immunity
Taken together, research shows that lipid rafts and lipoprotein interactions are not only essential
in the pathogenesis of infectious disease, but also in the compensatory immune response to ameliorate
infection (Figure 1). Dysregulation of lipid pathways may additionally contribute to inappropriate
leukocyte activation and inflammation in autoimmune disorders. [25]. While limited studies have
investigated the direct relationship between lipid metabolism and immune function in humans, these
compelling findings suggest that further research is warranted. As current evidence suggests the
role of cholesterol metabolism varies across disease pathologies, it is further essential to elucidate
the impact of lipid- and immune-modulating dietary components on risk and treatment of specific
infectious diseases and autoimmune disorders.
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Figure 1. Role of cellular cholesterol and lipoprotein metabolism in immune function. Arrows indicate 
the direction of lipid efflux. Pathways highlighted in blue indicate protective mechanisms against 
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pathogenesis. ABCA1: ATP-binding cassette transporter A 1; ABCG1: ATP-binding cassette 
transporter G 1; apoA1: apolipoprotein A 1; HCV: hepatitis C virus; HIV: human immunodeficiency 
virus; LDLR: low-density lipoprotein receptor; LPS: lipopolysaccharide; LTA: lipoteichoic acid; 
MCD: methyl--cyclodextrin; SR-BI: scavenger receptor class B type I. 
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treatment. Eggs are considered to be a rich source of dietary cholesterol, providing approximately 
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glycerophospholipids, sphingolipids, proteins and peptides, and carotenoids [20]. Similarly, animal 
studies evaluating the effects of dietary cholesterol often utilize Western-style diets that contain 
excessively high levels of cholesterol, and are often rich in total fat and carbohydrates, such as sucrose 
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3. Effects of Die ary Cholesterol and Egg Intake on Lipoprotein Metabolism and Immune Inflammation
Diets rich in cholesterol appear to have the c city to regulate immune function through
modulation of cellular cholesterol levels and lipoprotein metabolism [24]. The effects of dietary
cholesterol and cholesterol-rich foods, specifically eggs, on plasma lipids have been reviewed by
Blesso and Fernandez [97]; thus, the following sections focus on the effects of dietary cholesterol on
immunomodulatory lipid pathways. In interpreting these findings, it is important to note that human
studies evaluating the effects of dietary cholesterol often use whole eggs as the intervention treatment.
Eggs are considered to be a rich source of dietary cholesterol, providing pproximately 186 mg of
cholesterol per large egg [97,98]. In addition to cholesterol, eggs contain a ange of bioactive compounds
that can impact lipid metabolism and inflammatory pathways, including glycerophospholipids,
sphingolipids, proteins and peptides, and carotenoids [20]. Similarly, animal studies evaluating
the effects of dietary cholesterol often utilize Western-style diets that contain excessively high levels of
cholesterol, and are often rich in total fat and carbohydrates, such as sucrose [99,100]. Thus, for studies
using eggs or Western-style diets as vehicles for dietary cholesterol, it is not possible to attribute
observed effects solely to cholesterol within the context of a standard human diet.
3.1. Effects of Dietary Cholesterol and Egg Intake on Leukocyte Lipid Rafts and Cholesterol Metabolism
While few studies have assessed the effects of purified cholesterol on lipid raft formation
and immune function, compelling evidence suggests that egg intake can modulate cholesterol
metabolism in peripheral blood mononuclear cells (PBMCs), and that these effects are associated
with changes in ABCA1 expression, inflammatory potential, and HDL function [24,101,102]. In a
study by Andersen et al. [24], men and women classified with metabolic syndrome consumed
3 whole eggs per day vs. an egg white-based egg substitute for 12 weeks while following a moderate
carbohydrate-restricted diet. Interestingly, there was a statistical trend towards reduced cholesterol
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content of peripheral blood mononuclear cells (p = 0.057) in subjects who consumed whole eggs, while
PBMC cholesterol content did not change in participants who consumed the egg substitute. While there
were no significant differences in total lipid raft content in either group over the 12-week intervention,
changes in total PBMC cholesterol content positively correlated with changes in lipid raft content [24].
Interestingly, diets rich in carbohydrates, protein, and fat have been shown to differentially modulate
cholesterol loading of PBMCs in healthy subjects [103].
Egg consumption has additionally been shown to modify the expression of genes involved
in cellular cholesterol homeostasis in healthy, overweight, and metabolic syndrome populations.
In metabolic syndrome subjects consuming 3 eggs per day during carbohydrate restriction,
PBMC mRNA expression of ABCA1 and HMG-CoA reductase (HMGCR) increased, whereas
ABCG1 and LDL-receptor (LDLR) mRNA expression was unchanged [24]. Sterol regulatory
element-binding protein 2 (SREBP2)-mediated mRNA expression of HMGCR is known to increase
as a compensatory response to cellular cholesterol levels, in line with the observed trend toward
PBMC cholesterol reductions described above [24,104]. Conversely, in overweight men following
a carbohydrate-restricted diet for 12 weeks, consumption of 3 eggs per day reduced PBMC mRNA
expression of HMGCR and LDLR [105]. The discrepancy in HMGCR and LDLR expression patterns
between studies may be related to variability of dietary cholesterol absorption, as insulin resistant
individuals, such as those with metabolic syndrome, have a reduced absorption capacity compared to
those who are insulin sensitive, which may impact cellular cholesterol loading [106,107]. Accordingly,
PBMCs isolated from normal weight individuals are more enriched in cholesterol compared to PBMCs
from overweight individuals [103].
In a crossover study conducted with healthy men and women, consumption of 3 eggs per day
for 4 weeks reduced PBMC mRNA expression of HMGCR and SREBP2 compared to daily intake of
a choline bitartrate supplement [108]. These findings suggest the whole egg components—such as
cholesterol—impact markers of leukocyte cholesterol homeostasis beyond choline fractions. As described
above, egg-induced reductions in HMGCR, LDLR, and SREBP2 mRNA expression observed in
overweight and healthy adults may be due to compensatory mechanisms to suppress endogenous
cholesterol synthesis and exogenous cholesterol uptake via LDL, presumably due to increased cellular
cholesterol loading [104,105,108]. Accordingly, postprandial serum following egg intake in healthy men
has been shown to increase free cholesterol content of J774 macrophages ex vivo [109]. However, these
effects appear to be dose-dependent, as intake of 2 eggs per day for 4 weeks did not alter PBMC mRNA
expression of cholesterol genes in healthy men and women [110]. Together, these studies suggest that
egg intake alters leukocyte markers of cholesterol metabolism and lipid raft formation, and that dietary
dose, cholesterol absorption capacity, and insulin resistance status may impact cellular responses.
3.2. Effects of Dietary Cholesterol and Egg Intake on Lipoprotein Metabolism and Function
Alterations in PBMC cholesterol gene expression from egg intake are likely impacted by
interactions with lipoproteins. During weight maintenance, egg intake consistently increases
LDL-cholesterol and HDL-cholesterol levels in approximately one-third of healthy populations that are
considered to be “hyper-responders”, while often maintaining the LDL-cholesterol/ HDL-cholesterol
ratio [111–115]. During weight loss, egg intake often increases HDL-cholesterol levels, without raising
LDL-cholesterol [107,116,117]. Egg intake additionally increases LDL and HDL particle size, and
has been shown to increase plasma levels of apoA1 and activity of the HDL-associated antioxidant
paraoxonase 1 (PON1) [107,108,118–120]. Importantly, egg consumption during weight loss has
been shown to increase the cholesterol-accepting capacity of serum and reduce pro-inflammatory
SAA in metabolic syndrome subjects, which was associated with a trend toward reduced PBMC
cholesterol loading [24,101,102]. Conversely, consumption of 4 eggs per day for 4 weeks increased
SAA levels in healthy adults during weight maintenance, which may lead to a reduced efflux
capacity of HDL [121,122]. Investigation of leukocyte interactions with specific lipoprotein classes is
further warranted, as surprisingly, plasma LDL levels and ex vivo culture with lipoprotein-rich vs.
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lipoprotein-deficient media did not impact cholesterol loading of PBMCs from healthy volunteers [103].
Taken together, the variable effects of egg intake on lipoprotein profiles observed between healthy
vs. insulin resistant populations reflect differences in PBMC cholesterol loading and gene expression,
suggesting that lipoprotein profiles and functionality may differentially drive cholesterol metabolism
in leukocytes based on metabolic status.
3.3. Effects of Dietary Cholesterol and Egg Intake on Leukocyte Inflammation
Given the relationship between cellular cholesterol homeostasis and immune activation, it is
further likely that egg-induced changes to cholesterol metabolism and lipoprotein profiles impact
inflammatory leukocyte responses. In metabolic syndrome subjects consuming 3 eggs per day
during moderate carbohydrate restriction, PBMC mRNA expression of TLR4 increased after 12 weeks;
however, there was no change in LPS-induced TNFα and IL-1β secretion in ex vivo PBMCs. Conversely,
LPS-induced TNFα and IL-1β secretion increased over 12 weeks in ex vivo PBMCs derived from
subjects consuming an egg white-based substitute, suggesting that yolk-derived components may
have blunted responsiveness to bacterial LPS [24]. Plasma levels of TNFα were also reduced after
12 weeks in the whole egg group [102]. Egg intake has additionally been shown to reduce TNFα
and aspartate aminotransferase (AST) in type 2 diabetic patients [123], as well as decrease CRP and
increase anti-inflammatory adiponectin in overweight men during weight loss [124]. Conflicting results
have been reported in healthy adults, where egg intake has been shown to increase CRP [121] and
postprandial IL-6 [125], whereas fasting AST and alanine aminotransferase (ALT) are not affected [126].
Discrepancies in inflammatory responses across studies may be attributable to the degree of weight
loss, insulin sensitivity, cholesterol absorption, and modulation of lipoprotein profiles and leukocyte
cholesterol metabolism, as described above [24,101,106,109,127].
In animal models, Western-style diets have additionally been shown to promote transcriptional
and epigenomic reprogramming of myeloid progenitor cells, contributing to enhanced proliferative
and proinflammatory responses [128]. Cholesterol feeding has further been shown to dose-dependently
increase FoxP3+ T regulatory (Treg) cell numbers in the spleen and thymus of C57BL/6 mice,
with Treg cells derived from animals fed cholesterol-containing diets having a greater capacity to
suppress proliferation of CD4+ responder T cells. Despite the increase in anti-inflammatory Treg
cell populations, cholesterol feeding increased TCR responsiveness and proliferation in CD4+ T cells,
which may outweigh the suppressive effects of Treg cells and drive proinflammatory responses in
these models [129].
3.4. Summary: Effects of Dietary Cholesterol and Egg Intake on Lipid Metabolism and Immune Inflammation
Taken together, it appears that consumption of cholesterol-rich eggs and Western-style dietary
patterns impact leukocyte cholesterol metabolism and inflammatory potential, and that cellular
interactions with lipoproteins may contribute to these effects. Further, the effects of egg intake on lipid
metabolism and immune inflammation appear to vary across human populations and metabolic status.
These findings have important implications for the pathophysiology and management of infectious
disease and autoimmune disorders, suggesting that immunomodulatory lipid pathways may serve as
a therapeutic target for dietary interventions that modify cholesterol intake, or provide other dietary
bioactives that impact lipid metabolism.
4. Dietary Cholesterol Effects in Infectious Disease
Cholesterol-rich foods and dietary patterns have the potential to modulate cellular cholesterol
metabolism and lipoprotein function. Given the role of cholesterol-rich lipid rafts and lipoprotein
interactions in mediating infection by numerous bacterial and viral pathogens [38,39], understanding
the impact of dietary cholesterol on these pathways may influence prevention, assessment, and
treatment of disease. Interestingly, while diets rich in cholesterol may exasperate and increase the risk
of bacterial pulmonary infection in animal models and human populations, respectively, cholesterol
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intake during active infection may promote tissue-specific pathogen clearance and clinical outcomes
(Table 1). Studies in animals and humans further show that dietary cholesterol may exasperate viral
infections; however, responses may be gender-specific (Table 2). The following sections compare
findings from research studies evaluating the effects of dietary cholesterol on the pathogenesis of
infectious diseases.
Table 1. Comparative effects of dietary cholesterol on infection by bacterial pathogens.
Experimental
Model/Population Dietary Conditions Effect Reference
Tuberculosis
ApoE-deficient mice High cholesterol (1.25%) diet
↓ Th1 response
↑ bacterial burden, lung inflammation,
early onset mortality
[130]
Wild type and SR-BI
knockout mice High cholesterol (1.25%) diet
↑ bacterial burden
↔ pulmonary histopathology, cytokine
expression
[131]
Men and women in the
Singapore Chinese
Health Study, n = 63,257
Observational study ↑ increased risk of active TB [132]
Active pulmonary TB





↓ positive sputum cultures,
sputum production [133]
Pneumonia
C57BL/6 mice Cholesterol-rich (1.25%)Western Diet
↓ pulmonary bacterial clearance,
pulmonary PMN numbers and chemotaxis,
LPS-induced pulmonary TNFα, MIP-2,
NF-kB p65 subunit activation
↑ rate of clearance of pathogens from
blood, serum TNFα, MIP-2





600 mg/day from egg yolks for
10 days
↓ plasma CRP, IL-6
↑ SAPSII and SGA scores [135]
↓: Decreased; ↑: increased; ↔: no change or difference between groups. Abbreviations: apoE: apolipoprotein E; CRP:
C-reactive protein; IL-6: interleukin 6; LPS: lipopolysaccharide; MIP-2: macrophage-inflammatory protein 2; NF-kB:
nuclear factor k B; PMN: polymorphonuclear cells; SAPSII: Simplified Acute Physiology Score II; SGA: Subjective
Global Assessment; SR-BI: scavenger receptor class B type I; TB: tuberculosis; Th1: T helper 1 lymphocytes; TNFα:
tumor necrosis factor α.
Table 2. Effects of dietary cholesterol on the pathophysiology of viral infections.
Experimental







↑ risk for fibrosis and/or cirrhosis [136]
Chronic HCV patients
from the HALT-C Trial




↑ risk of liver-related death and
transplantation in women
↔ relationship between dietary





(185 mg/day) diet for 30 days
↑ % Treg cells, PBMC mRNA expression of
LXRα, LXRβ, SREBP-1c, ABCA1
↓ % Th17 cells, serum IL-17, IL-22, TGFβ,
HA
[26]
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Table 2. Cont.
Experimental







↑ peak viral loads, rate of disease
progression, plasma IL-18, incidence of
co-infections, body wasting, risk of
SIV-related death
[138]
↓: Decreased; ↑: increased; ↔: no change or difference between groups. Abbreviations: ABCA1: ATP-binding
cassette transporter A 1; AIDS: acquired immunodeficiency syndrome; apoE: apolipoprotein E; HA: hyaluronic
acid; HCV: hepatitis C virus; HIV: human immunodeficiency virus; IL-17: interleukin 17; IL-18: interleukin 18;
IL-22: interleukin 22; LXRα: liver X receptor α; LXRβ: liver X receptor β; PBMC: peripheral blood mononuclear
cell; SIV: simian immunodeficiency virus; SREBP-1c: sterol regulatory binding protein 1 c; TB: tuberculosis;
TGFβ: transforming growth factor β; Th17: T helper 17 lymphocytes; TNFα: tumor necrosis factor α; Treg: T
regulatory lymphocytes.
4.1. Tuberculosis
Tuberculosis is one of the leading causes of death from infectious disease worldwide [139].
Tuberculosis can further lead to, and be complicated by, malnutrition and nutrient deficiencies [140].
Research on nutritional support for tuberculosis has been inconsistent, leading to a lack of nutritional
guidelines and recommendations for tuberculosis treatment [140]. Lipid raft formation is essential
for Mycobacterium tuberculosis internalization and survival in host cells [141], whereas serum lipid
levels are reduced and negatively associated with clinical radiological and smear positivity measures
on pulmonary tuberculosis patients [142,143]. Thus, cellular cholesterol enrichment may promote
M. tuberculosis infection, whereas systemic cholesterol depletion may contribute to disease progression.
Accordingly, conflicting effects of dietary cholesterol on tuberculosis pathology have been reported
(Table 1). In apolipopotein E (apoE)-deficient mice, high cholesterol feeding exasperated M. tuberculosis
infection, as evidenced by reduced T helper 1 (Th1)-mediated immune responses, increased bacterial
burden and lung tissue inflammation, and early onset mortality [130]. Schafer et al. [131] additionally
found that high cholesterol (1.25% cholesterol) feeding resulted in a greater bacterial burden of
M. tuberculosis H37Rv in both wild type and SB-BI knockout mice, as compared to mice consuming a
low cholesterol (0.15%) diet. However, pulmonary histopathology and cytokine expression did not
differ between diet treatment groups [131]. In 63,257 men and women participating in the Singapore
Chinese Health Study, dietary cholesterol intake was dose-dependently associated with risk of active
tuberculosis, where individuals consuming the greatest amount of cholesterol had the greatest risk
of tuberculosis [132]. Conversely, patients who consumed a cholesterol-rich diet (800 mg/day) while
undergoing inpatient treatment for active pulmonary tuberculosis had faster reductions in positive
sputum cultures and sputum production, as compared to patients receiving a low cholesterol diet
(250 mg/day), suggesting a more rapid clearance of active infections [133]. Together, these findings
suggest that habitually high intakes of dietary cholesterol may promote M. tuberculosis infection,
whereas supplementation during active infection may promote pathogen clearance and recovery.
4.2. Pneumonia
In addition to tuberculosis, dietary cholesterol appears to impact the pathogenesis of other
types of pulmonary infections, including pneumonia. Klebsiella pneumoniae—a pneumonia-causing
Gram-negative pathogen—additionally utilizes host lipid rafts for infection, whereas depletion
of host cell cholesterol by MβCD and LXR activation impairs K. pneumonia internalization and
subsequent host defenses [144,145]. These findings suggest that cholesterol enrichment may promote
K. pneumonia clearance.
Animal studies have demonstrated that high cholesterol feeding modifies the lipid composition
of pulmonary tissue. In mice fed a high cholesterol (2%) diet, surface-active film from pulmonary
surfactant was found to be enriched in cholesterol, which was associated with reduced surface-active
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film stability [146]. High intake of dietary cholesterol has also been associated with modification
of the glycerophospholipid composition of lung surfactant, increasing phosphatidylglycerol while
decreasing phosphatidylethanolamine [147]. Interestingly, C57BL/6 mice fed a cholesterol-rich (1.25%)
Western diet exhibited compromised bacterial clearance from pulmonary tissues, despite more rapid
clearance of pathogens from the bloodstream [134]. High cholesterol feeding additionally increased
serum levels of pro-inflammatory IL-17 and its target protein, macrophage-inflammatory protein 2
(MIP-2), while suppressing LPS-induced pulmonary TNFα, MIP-2, and nuclear factor k B (NF-kB)
p65 subunit activation. Lung-derived polymorphonuclear (PMN) cell numbers and chemotaxis were
similarly reduced by high cholesterol feeding, while extra-pulmonary bacterial burden in spleen and
liver were significantly reduced. Overall, survival rates did not statistically differ between high- and
low-cholesterol groups, although the authors note that the high cholesterol group tended to have
greater survival [134]. Together, these findings suggest that cholesterol dose-dependently modulates
pathways of K. pneumonia in a tissue-specific manner, which may ultimately impact disease outcomes.
The effects of dietary cholesterol on clinical outcomes of pneumonia have additionally been
investigated in humans. In a study by Wang and Hong [135], pneumonia patients were supplemented
with an additional 600 mg of cholesterol from egg yolks per day for 10 days. Interestingly, patients
receiving egg yolks exhibited significantly lower high-sensitivity CRP (hsCRP) levels compared to the
control group, in addition to lower plasma IL-6. Egg yolk supplementation also improved ratings for
simplified acute physiology score II (SAPS II) and Subjective Global Assessment, which is indicative of
reduced disease severity and improved nutritional status [135]. While total cholesterol levels increased
following egg yolk intake, markers of HDL function and leukocyte cholesterol metabolism were not
assessed. Given that these parameters are modified by egg intake in other studies, it is possible that
these factors played a role in the immune response [24,101,102]. Thus, while excess dietary cholesterol
may exasperate pulmonary dysfunction during K. pneumonia infection in animal models [134], systemic
effects and egg consumption in humans may lead to clinical benefits overall (Table 1).
4.3. Hepatitis C Virus
In addition to infectious diseases affecting pulmonary tissues, dietary cholesterol may further
impact mechanisms of viral infection by hepatic pathogens (Table 2). As described above, HCV
infection can be mediated by lipoprotein-dependent mechanisms, including viral transport by
lipoproteins and cellular uptake by the LDL-receptor and SR-BI [74,75]. Using stable isotope methods,
Lambert et al. [148] demonstrated that individuals with HCV infection displayed increased rates of
fasting whole body and hepatic lipogenesis, as evidenced by greater levels of de novo fatty acids
in plasma triacylglycerols (TAG) and VLDL-TAG, respectively. Interestingly, de novo synthesis of
free cholesterol and cholesteryl esters was significantly reduced in HCV patients [148]. Additional
studies suggest that while HCV infection induces expression of genes involved in endogenous
cholesterol synthesis, chemical intermediates may be diverted into non-cholesterol pathways to
support viral replication [148–150]. Accordingly, Corey et al. [151] demonstrated that patients with
HCV infection exhibit decreased total and LDL-cholesterol levels, which are normalized following
successful HCV treatment.
Given the disruptions in hepatic metabolism, HCV-infected individuals are at greater risk of
developing hepatic fibrosis, cirrhosis, and carcinoma with disease progression [152,153]. Consequently,
HCV patients may be more susceptible to inflammatory damage from excess dietary cholesterol.
Dietary cholesterol has been shown to promote hepatic inflammation, steatosis, and fibrosis in animal
models, whereas these effects may be exasperated by concomitant high-fat and high-sucrose feeding
in Western-style diets [154–157]. In 608 patients with chronic HCV infection, individuals with greater
intake of dietary cholesterol (224–310 mg/day and >310 mg/day) had increased risk for disease
progression toward fibrosis and/or cirrhosis, as defined by increases in histological Ishak fibrosis
scores in liver biopsies [136]. Interestingly, Yu et al. [137] further demonstrated that dietary cholesterol
intake was dose-dependently associated with increased risk of liver-related death and transplantation
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in women with chronic HCV infection and advanced fibrosis or compensated cirrhosis, whereas a
relationship between dietary cholesterol and liver disease progression was not observed in men. Female
mice have previously been shown to exhibit greater efficiency of cholesterol absorption, increased
hepatic cholesterol loading, and larger increases in bile acid pools in response to dietary cholesterol,
suggesting that females may be more sensitive to exogenous cholesterol intake [158].
In a pilot intervention trial, subjects with chronic HCV infection following a normocaloric
low-cholesterol (185 mg/day) diet for 30 days had an increased percentage of anti-inflammatory
Treg lymphocytes as compared to baseline, in addition to reduced pro-inflammatory T helper 17
(Th17) lymphocytes, and lower serum levels of IL-17, IL-22, transforming growth factor β (TGFβ),
and hyaluronic acid [26]—a biomarker that positively correlates with hepatic fibrosis [159]. Elevated
Th17-mediated responses have been implicated in promoting hepatic inflammation, steatosis, and
hepatocellular carcinoma [160,161]. PBMC mRNA expression of LXRα, LXRβ, sterol regulatory binding
protein 1c (SREBP-1c), and ABCA1 additionally increased following the low cholesterol diet [26], which
may represent a compensatory mechanism in response to changes in cellular cholesterol levels [162].
Similar to what has been observed with cholesterol-rich egg feeding [24], these findings suggest
that restricting dietary cholesterol modulates blood leukocyte lipid metabolism and inflammatory
profiles [26]. Given that Th17 lymphocytes have been implicated in numerous inflammatory diseases
and immune disorders [163], the role of dietary cholesterol in regulating this T lymphocyte population
warrants further investigation.
4.4. Human Immunodeficiency Virus (HIV)
HIV pathogenesis similarly involves HDL and ABCA1 pathways, where cholesterol depletion
and efflux appear to confer therapeutic effects [69,71–73]. Egg intake has previously been shown to
increase PBMC expression of ABCA1 and the cholesterol-accepting capacity of serum [24,101], as well
as modify mRNA expression of genes involved in cholesterol homeostasis [24,105,108], suggesting that
cholesterol-rich foods may modulate mechanisms of HIV infection. While research on dietary cholesterol
intake and HIV pathogenesis is limited, Mansfield et al. [138] examined the effects of a high cholesterol
(1%)/high fat (~40% of energy) diet on simian immunodeficiency virus (SIV) progression to acquired
immunodeficiency syndrome (AIDS) in infected macaques primates. Interestingly, animals fed the high
cholesterol/high fat diet exhibited greater peak viral loads compared to animals fed a control diet. High
cholesterol/high fat diet feeding additionally resulted in faster disease progression and risk of SIV-related
death, corresponding to elevated IL-18 levels in plasma, as well as greater incidence of concomitant
infections and body wasting [138]. Elevated IL-18 levels have additionally been observed in HIV-infected
patients, and may be involved in promoting viral replication, lipodystrophy, and Th2 lymphocyte
responses that accelerate disease progression [138,164–166]. Further clinical research is warranted to
determine whether cholesterol-rich foods or dietary patterns impact lymphocyte cholesterol loading and
efflux in HIV within the context of initial infection and treatment in humans.
5. Dietary Cholesterol Effects in Autoimmune Disease
In addition to infectious diseases, dietary cholesterol has the potential to impact risk, severity,
and treatment of chronic autoimmune disorders. Potential targets of exogenous cholesterol may
include regulation of leukocyte cholesterol metabolism and lipid raft formation, alteration of
lipoprotein profiles and immunomodulatory functions, and modification of systemic tissue stress
and inflammation [24,101,102,108,167]. Interestingly, dietary cholesterol appears to exasperate
autoimmune inflammation and risk, whereas cholesterol restriction reduces inflammation and
improves clinical outcomes (Table 3). An exception to this trend is observed in models of demyelinating
autoimmune disorders, where cholesterol supplementation improves central nervous system (CNS)
integrity and inflammation [168]. The following sections highlight research evaluating the effects
of dietary cholesterol on the pathophysiology of autoimmune conditions in animal models and
human populations.
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Table 3. Differential effects of dietary cholesterol on the pathophysiology of autoimmune disorders.
Experimental




Cholesterol-rich (1% and 2%)
diets
↑ bronchoaveolar inflammation,




C57BL/6 mice Cholesterol-rich (2%) diet
↑ IL-5, PGE2, MCP-1, eosinophils
numbers in bronchoalveolar lavage fluid




Men and women from The
45 and Up Study, n = 156,035
Diets rich in meats, poultry,
and seafood ↑ odds of asthma/hayfever diagnosis [170]
Men and women from The
45 and Up Study, n = 156,035 Diets rich in cheese
↑ odds of asthma/hayfever diagnosis in
men




RA patients, n = 47 Gluten-free, vegan diet for ninemonths vs. non-vegan diet ↑ clinical improvement by ACR20 criteria [171]
RA patients, n = 24 Very low-fat (10% of energy)vegan diet
↓ joint pain and swelling
↑ joint mobility [172]
RA patients, n = 53
7–10 day fast →
gluten-free vegan diet vs.
standard non-vegan diet
↓ number of tender and swollen joints,
pain score, duration of morning stiffness,




7–10 day fast →
gluten-free vegan diet →
vegetarian diet vs. a standard
non-vegan diet
↓ leukocyte and platelet counts, total IgG
and IgM rheumatoid factor, calprotectin,
C3 and C4 complement proteins
[174]
APOE*3Leiden.CETP mice Cholesterol-rich (0.1% and 0.3%)Western diets
↑ joint inflammation, osteoarthritis
development [28]
Systemic Lupus Erythematous
ApoE/LXRβ-deficient mice Cholesterol-rich (0.21%)Western diet
↑ cholesterol accumulation in spleen and
lymph nodes, T cell priming, B cell
expansion, autoantibody production
* Note: HDL-mediated efflux suppressed




EAE mouse model of MS High cholesterol (5%) diet
↓ spinal immune cell infiltration, mRNA
expression of TNFα, IL-17, IFNγ,
GM-CSF, MHCII












model of MS High cholesterol (2%) diet ↑ remyelinization [168]
↓: Decreased; ↑: increased; ↔: no change or difference between experimental and control groups. Abbreviations:
apoE: apolipoprotein E; CETP: cholesteryl ester transfer protein; CRP: C-reactive protein; EAE: experimental
autoimmune encephalomyelitis; GM-CSF: granulocyte-monocyte colony stimulating factor; IgG: immunoglobulin
G; IgM: immunoglobulin M; IL-12: interleukin 12; IL-17: interleukin 17; IL-4: interleukin 4; IL-5: interleukin 5; IFNγ:
interferon γ; LXRβ: liver X receptor β; MCP-1: monocyte chemoattractant protein 1; MS: multiple sclerosis; PGE2:
prostaglandin E2; RA: rheumatoid arthritis; TNFα: tumor necrosis factor α.
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5.1. Asthma
Asthma is a chronic inflammatory disorder with a potential autoimmune etiology that affects the
lower respiratory tract [175,176]. High cholesterol diets lead to enrichment of pulmonary surfactant
cholesterol and phosphatidylglycerol levels, which reduces surface-active film stability and may lead
to altered pulmonary leukocyte activity and immunity to pulmonary pathogens [133,134,146,147].
In an ovalbumin-sensitized C57BL/6 mouse model for asthma, diets rich in cholesterol (1% and 2%)
dose-dependently induced greater bronchoaveolar inflammation, as evidenced by increased levels
of eosinophils, IL-5, and cysteinyl leukotrienes compared to control fed mice (0.02% cholesterol) [27].
In a similar study, Yeh and Huang [169] demonstrated that ovalbumin-sensitized mice fed high
cholesterol (2%) diets exhibited increased pro-inflammatory IL-5, prostaglandin E 2 (PGE2), monocyte
chemoattractant protein 1 (MCP-1) and eosinophil numbers in bronchoalveolar lavage fluid, in addition
to greater IL-4 and interferon γ (IFNy) production by lung-derived lymphocytes. Dietary cholesterol
additionally reduced levels of IL-12, which has been shown to have both pro-inflammatory effects
and therapeutic potential in asthma [177,178]. Interestingly, the addition of pravastatin treatment
reduced pulmonary inflammation, with the exception of increasing IL-12 [169]. In a study evaluating
156,035 Australian adults from The 45 and Up Study, Rosenkranz [170] et al. demonstrated that men
and women who consumed diets rich in meats, poultry, and seafood had greater odds of receiving a
diagnosis for asthma/hayfever. These findings suggest that cholesterol-containing animal foods may
contribute to the development of asthma or hayfever. However, these associations may be gender- and
food source-specific, as cheese was found to be positively associated with asthma and hayfever in men,
whereas dietary patterns consisting of cheese and whole grain bread were found to be protective in
women [170]. Additional observational studies have found neutral or positive associations between
Western-style diet patterns and asthma (Table 3) [179,180]. Further intervention studies are needed to
elucidate the impact of dietary cholesterol on asthma in humans, and determine whether variability in
lipid metabolism plays a role in the controversial findings observed between genders.
5.2. Rheumatoid Arthritis
RA is a chronic autoimmune disorder characterized by severe joint inflammation and damage.
Activated T lymphocytes are found within synovial joint fluid from RA patients, yet they exhibit
impaired TCR responsiveness and proliferative capacity [87,88]. Proinflammatory HDL and reduced
HDL-mediated cholesterol efflux has additionally been observed in RA patients [94,181–183],
whereas RA treatment improves markers of HDL function [184] and increases PBMC mRNA
ABCA1 expression [185]. Increases in HDL-cholesterol have additionally been associated with
improvements in radiographic hand osteoarthritis [186]. However, it is unclear whether cholesterol
metabolism or lipid raft formation is modified within activated T cell populations, or whether
cholesterol-rich diets can directly modulate HDL dysfunction and T lymphocyte activity in joint
tissues of RA patients [24,101]. Interestingly, dietary regimens that are low in cholesterol or
cholesterol-free—including medically supervised fasting (7–10 days), vegan diets, and lactovegetarian
diets—have been shown to reduce inflammation and improve clinical measures of RA [187].
Hafström et al. [171] demonstrated that a greater percentage of RA patients following a gluten-free
vegan diet for at least nine months exhibited clinical improvement according to the American
College of Rheumatology 20 (ACR20) criteria, as compared to patients consuming a non-vegan diet.
Patients following a 4-week, very low-fat diet (10%) vegan diet additionally experienced improved
RA symptoms, including a reduction in pain, joint swelling, and joint mobility [172]. Vegan and
vegetarian diets have further been shown to reduce total cholesterol and LDL-cholesterol levels in RA
patients [188,189], as well as reduce leukocyte counts and pro-inflammatory CRP [173,174]. Conversely,
high cholesterol diets have been shown to exasperate joint inflammation and osteoarthritis development
in APOE*3Leiden.CETP mice, potentially due to cholesterol-induced inflammation and joint cartilage
degradation [28,190,191]. These findings suggest that dietary cholesterol restriction improves RA
outcomes, yet further research is warranted to elucidate the mechanisms by which this occurs.
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5.3. Systemic Lupus Erythematous (SLE)
Systemic Lupus Erythematous (SLE) is classified as a systemic autoimmune disease, where
autoreactive T and B lymphocytes mediate the production of autoantibodies against nuclear
components. Clinical consequences of SLE include multiorgan tissue inflammation and injury [192].
SLE patients often present with dyslipidemia and dysfunctional HDL, which lead to an increased risk
of cardiovascular disease, and potentially exasperate hyper-responsive, proinflammatory T lymphocyte
responses [80,81,92,95,193,194]. Dietary recommendations for SLE patients often include restrictions
of dietary cholesterol as a means to address dyslipidemia and cardiovascular disease risk; however,
few studies have evaluated the direct effects of dietary cholesterol on autoimmune inflammation and
clinical outcomes of SLE [195–197]. In ApoE/LXRβ-deficient mice, feeding of a cholesterol-containing
(0.21%) Western diet resulted in the development of a lupus-like disease [100]. Western diet feeding
increased cholesterol accumulation in the spleen and lymph nodes, while enhancing T cell priming,
B cell expansion, and production of autoantibodies. Conversely, B cell expansion and autoantibody
production was suppressed by enhancing mechanisms of HDL-mediated cholesterol efflux [100].
While additional studies are required to fully elucidate the effects of dietary cholesterol SLE-related
immune dysfunction in humans, current evidence suggests that excess cholesterol loading may be
involved in the pathogenesis of SLE-like autoimmunity, whereas dietary cholesterol restriction and
lipid efflux-promoting therapeutics may support clinical management of SLE complications.
5.4. Multiple Sclerosis
Multiple sclerosis (MS) is a proinflammatory autoimmune disorder that causes demyelinization
and damage of CNS cells [198]. While dietary cholesterol may exasperate inflammation in certain
autoimmune conditions, studies have found that exogenous cholesterol may improve inflammation
and degenerative pathways associated with MS. Berghoff et al. [168] demonstrated that high cholesterol
(5%) feeding reduced immune cell infiltration into the spinal cords of experimental autoimmune
encephalomyelitis (EAE) murine models of MS, in addition to reducing proinflammatory spinal
cord mRNA expression of TNFα, IL-17, IFNγ, granulocyte-monocyte colony-stimulating factor
(GM-CSF), and major histocampatability complex II (MHCII). However, dietary cholesterol did not
improve overall clinical scoring of CNS lesions and disease pathology in EAE mice. Interestingly,
high cholesterol (2%) feeding promoted remyelinaization in cuprizone- and lysolecithin-induced
mouse models of MS. Dietary cholesterol additionally increased oligodendrocyte precursor cell
proliferation, oligodendrocyte differentiation, and improved motor function in the cuprizone-treated
mice, while it was unable to prevent initial demyelinization [168]. These findings may be translatable
to other demyelinating disorders, as cholesterol has been shown to be a rate-limiting factor in
myelin production in CNS cells [199]. Accordingly, Saher et al. [200] found that dietary cholesterol
improved myelination, inflammation, and motor control in a mouse model of Pelizaeus-Merzbacher
disease—a fatal leukodystrophy condition of genetic etiology that currently lacks effective treatment
options. Thus, dietary cholesterol may serve as a safe and effective therapeutic strategy to address
demyelinating disorders.
6. Conclusions
Overall, it is clear that cholesterol metabolism plays an important, yet complex and controversial
role in the regulation of immunity and inflammatory disease risk (Figure 2). Consumption of
dietary cholesterol, specifically coming from eggs, has been shown to modulate leukocyte cholesterol
metabolism, lipid raft dynamics, and inflammatory potential, while additionally modulating
lipoprotein profiles and markers of HDL function [24,101]. Interestingly, evidence from human
studies suggests that these pathways are affected by cholesterol dose and metabolic status, suggesting
that efficiency of dietary cholesterol absorption, the presence of insulin resistance, and weight loss can
impact the immunomodulatory response to exogenous cholesterol [105,106,108,110]. Research from
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animal and human studies further demonstrates that cholesterol-rich dietary patterns differentially
impact pathophysiology and clinical outcomes of distinct infectious diseases by various bacterial
and viral pathogens, and that dietary cholesterol may either exasperate or mitigate autoimmune
dysfunction [26,100,133,135,168,169]. However, further human studies and clinical trials are required
to determine whether altered leukocyte cholesterol metabolism, lipoprotein profiles, or metabolic
status underlie the variable effects of cholesterol-rich diet intake on infectious and autoimmune
disease pathophysiology. It is additionally essential to elucidate the contributions of confounding
dietary bioactives in these pathways, and evaluate whether other functional foods known to modulate
lipid metabolism can impact immunity via similar mechanisms. Together, the findings presented in
this review highlight a significant role for dietary cholesterol in human health beyond the scope of
cardiovascular disease.
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